ArticleOncogene2002
Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 75 citations in OpenAlex.
- Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.Frontiers in immunology · 2021Article
- ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.Journal of oncology · 2017Review
- Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Oncotarget · 2016Article
- Affibody-mediated PET imaging of HER3 expression in malignant tumours.Scientific reports · 2015Article
- Article
- Regulation of ERBB3/HER3 signaling in cancer.Oncotarget · 2014Review
- Kaempferol Downregulates Insulin-like Growth Factor-I Receptor and ErbB3 Signaling in HT-29 Human Colon Cancer Cells.Journal of cancer prevention · 2014Article
- Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.Journal of the National Cancer Institute · 2014Article
- Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.Cancer science · 2013Article
- Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells.International journal of molecular medicine · 2013Article
- The promise of anti-ErbB3 monoclonals as new cancer therapeutics.Oncotarget · 2012Review
- Expression of NRG1 and its receptors in human bladder cancer.British journal of cancer · 2011Article
- ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.Cancer biology & therapy · 2010Article
- Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening.Molecular cancer therapeutics · 2009Article
- Challenging issues in molecular-targeted therapy.Therapeutics and clinical risk management · 2009Article
- The ERBB3 receptor in cancer and cancer gene therapy.Cancer gene therapy · 2008Review
- Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth.Oncogene · 2005Article
- Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.World journal of gastroenterology · 2005Article
- ERBB receptors and cancer: the complexity of targeted inhibitors.Nature reviews. Cancer · 2005Review
- Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as reflected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.